Vitamin K2 + D3
80/100
This product is generally safe
- Vitamin D3: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)
- 100% of ingredients have research evidence
C
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
⚠️ Vitamin D3: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)
Label Data
1 Capsule(s)
Serving Size
250
Servings
Vitamin
Product Type
100%
Evidence Coverage
Supplement Facts — Evidence Check
125 mcg
(625% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.2× (UL: 0.1 mg)
📚 604 studies (Tier A: 16, B: 251)
90 mcg
(75% DV)
✅ Within RDA (0.8× RDA of 0.12 mg)
📚 273 studies (Tier A: 9, B: 175)
Other Ingredients
Microcrystalline Cellulose
Modified Cellulose
Magnesium Stearate
Silicon Dioxide
Label Claims — Verification
❓
Nutrient
❓
All Other
❓
Structure/Function
All Other (100% of products)
Structure/Function (84% of products)
Nutrient (73% of products)
Target Groups
Adult (18 - 50 Years)
Women (not pregnant or lactating)
Gluten Free
Product Information
📋 Directions for Use
Directions: As a dietary supplement for adults, take 1 capsule daily, preferably with a meal or as directed by a healthcare professional.
⚠️ Warnings & Precautions
Warnings: Do not take this product if you are pregnant or nursing. Consult a physician before taking this product if you have a medical condition or are taking medication, especially anticoagulant drugs.
Do not use if seal under cap is broken or missing.
Keep out of reach of children.
🧪 Formulation Notes
Futurebiotics Vitamin K2 (...ow, 250 Vegetarian Capsules
Vitamin K2 + D3 With vitamin K2 as MK-7
2 in 1 Support Supports strong bones Healthy cardiovascular support
Free of gluten and soy Lab Tested GMO Free
Additional Information
New
Protect from light.
Lab Tested GMO Free
Product Details
UPC / SKU
X0031HQWW5
DSLD Entry Date
2024-12-21
Product Type
Vitamin
Form
Capsule
Brand
Futurebiotics
DSLD ID
320009
Data Updated
2026-04-11
Research Evidence
332
Research Sources
59
Avg Quality Score
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
A
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Compare Similar Products
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Natural Vitamin K2 45 mcg
Doctor's Best
100
K 100 mcg
Thompson
100
Vitamin K2 300 mcg MK-7
Innerzyme
100